The potential $2.9 billion deal stands the New Jersey company in good stead after recent disappointing results in its ALS ...

The U.S. biotech company Spyre Therapeutics announced yesterday that it has dosed the first participants in two Phase 1 ...

Eisai and Biogen have officially launched Leqembi (lecanemab) in South Korea, marking a significant step in Alzheimer’s ...

MariTide is being studied for the treatment of obesity and Type 2 diabetes and demonstrated weight loss at 52 weeks.

The acquisition will grant Roche full ownership over a pipeline of allogeneic CAR-T therapy candidates, including two ...

California-based BridgeBio has secured US FDA approval for its lead candidate drug, acoramidis (brand name Attruby) for ...

We’re thrilled to announce that we have migrated BioPharmaReporter to a new platform. Our expert coverage of the sector won’t ...

Despite disappointing results in the genetic neurodegenerative disorder, the drug shows potential for treating obesity.

The promising trial results put icotrokinra on track to fulfill its potential as a best in class oral therapeutic for the ...

Steritas LLC, a Boston-based company committed to improving care for patients treated with steroids, has announced a multi-year licensing agreement with argenx, a global leader in immunology. The ...